Article
Medicine, Research & Experimental
Francisco Quinonero, Cristina Mesas, Jose A. Munoz-Gamez, Cristina Jimenez-Luna, Gloria Perazzoli, Jose Prados, Consolacion Melguizo, Raul Ortiz
Summary: Inhibition of PARP1 has been found to enhance the sensitivity of pancreatic cancer cells to gemcitabine, reducing tumor growth and migration, as well as decreasing drug resistance and angiogenesis. This suggests that targeting PARP1 could be a promising strategy for the treatment of pancreatic cancer.
BIOMEDICINE & PHARMACOTHERAPY
(2022)
Article
Chemistry, Medicinal
Nur Aininie Yusoh, Paul R. Tiley, Steffan D. James, Siti Norain Harun, Jim A. Thomas, Norazalina Saad, Ling-Wei Hii, Suet Lin Chia, Martin R. Gill, Haslina Ahmad
Summary: Through screening, three effective drug combinations were identified for Olaparib in BRCA-proficient triple-negative breast cancer cells, including curcumin and two ruthenium-polypyridyl metallomacrocycles. These combinations were shown to enhance DNA damage and induce apoptosis in cell and model experiments, with low cytotoxicity and toxicity effects.
JOURNAL OF MEDICINAL CHEMISTRY
(2023)
Article
Pharmacology & Pharmacy
Yanting Wang, Di Du, Jun Yang, Alan H. Lau, Yuanyuan Dai, Wangjun Qin, Ning Li, Guohui Li
Summary: A pharmacist-led olaparib follow-up program was established for ovarian cancer patients. The study found that the types of adverse drug reactions (ADRs) were similar to previous clinical trial observations, and identified drug-related problems for which pharmacists provided suggestions.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Pharmacology & Pharmacy
Na Li, Huanrui Zheng, Yanlei Huang, Bin Zheng, Hongfu Cai, Maobai Liu
Summary: The study found that olaparib was more cost-effective than placebo for maintenance therapy in metastatic pancreatic cancer in both China and the United States.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Kitti Andreidesz, Balazs Koszegi, Dominika Kovacs, Viola Bagone Vantus, Ferenc Gallyas, Krisztina Kovacs
Summary: The study found that triple-negative breast cancer cells are more resistant to combined treatment compared to hormone receptor-positive breast cancer cells, and no synergistic effect was observed between olaparib and oxaliplatin, while the Akt pathway inhibitor enhanced the cytostatic properties of the platinum compound.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Editorial Material
Oncology
Jose Perez-Garcia, Maria Gion, Javier Cortes
Summary: The phase II studies on breast cancer using the I-SPY2 platform have shown promising results in accelerating the development of new treatments. Adding durvalumab and olaparib to standard neoadjuvant chemotherapy significantly increased the pathological complete response rate in HER2-negative breast cancer patients, regardless of hormone receptor status.
Article
Nanoscience & Nanotechnology
Francisco Quinonero, Belen Parra-Torrejon, Gloria B. Ramirez-Rodriguez, Victor Garces, Jose M. Delgado-Lopez, Cristina Jimenez-Luna, Gloria Perazzoli, Jose Prados, Raul Ortiz
Summary: This study functionalized calcium phosphate-based nanoparticles with Olaparib and ascorbic acid to enhance their individual effects in treating pancreatic cancer. The resulting dual nanosystem showed a gradual release of Olaparib and ascorbic acid, demonstrating a better cytotoxic effect and apoptosis-mediated cytotoxic effect in human pancreatic ductal adenocarcinoma cell line. In vivo studies further confirmed the therapeutic benefits of the nanoparticle system in terms of tumor volume reduction and survival improvement.
INTERNATIONAL JOURNAL OF NANOMEDICINE
(2023)
Article
Oncology
Joseph W. Kim, Dana B. Cardin, Ulka N. Vaishampayan, Shumei Kato, Steven R. Grossman, Peter M. Glazer, Yu Shyr, S. Percy Ivy, Patricia M. LoRusso
Summary: The combination of cediranib and olaparib did not show significant clinical activity in patients with metastatic pancreatic ductal adenocarcinoma without known BRCA mutations, with no objective responses observed in the study.
Article
Oncology
Georgios I. Papageorgiou, Evangelos Fergadis, Nikos Skouteris, Evridiki Christakos, Sergios A. Tsakatikas, Evangelos Lianos, Christos Kosmas
Summary: PARP inhibitors are increasingly being used in cancer treatment, especially in tumors associated with BRCA deficiency. Preclinical data support their use in tumors exhibiting BRCAness or HRD, both as monotherapy and in combination with chemotherapy. This treatment approach has shown effectiveness in patients with ATM-deficient colorectal cancer.
FRONTIERS IN ONCOLOGY
(2021)
Article
Chemistry, Multidisciplinary
Mubin Tarannum, Md Akram Hossain, Bryce Holmes, Shan Yan, Pinku Mukherjee, Juan L. Vivero-Escoto
Summary: A mesoporous silica nanoparticle (MSN)-based platform is developed for the safe and ratiometric co-delivery of Gem and cisplatin (cisPt) in pancreatic ductal adenocarcinoma (PDAC). The nanoparticles demonstrate synergistic therapeutic outcomes in mouse models and show potential for overcoming resistance to Pt-based drugs. Overall, the platform offers a promising approach for targeted therapy in PDAC.
Letter
Medicine, General & Internal
Kazuki Nozawa, Akiyo Yoshimura, Hiroji Iwata
Summary: The OlympiA trial showed that adjuvant olaparib significantly improved invasive and distant disease-free survival rates for early breast cancer patients with BRCA1 or BRCA2 mutations. It also reduced recurrence of local lesions and lowered the risk of contralateral breast cancer and second primary ovarian cancer through prophylactic surgery.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Jae Young Lee, Do-Youn Oh, Kyung-Hun Lee, Sang Hyub Lee, Dong Ho Lee, Kookjin Kang, Soo Yeon Kang, Dong Hyuk Park
Summary: The combined treatment of focused ultrasound and chemotherapy (nPac/Gem) was investigated for patients with unresectable pancreatic cancer. The study found that using a focused ultrasound intensity of 1.5 to 2.5 kW/cm(2) was safe and showed positive efficacy in terms of tumor size, CA 19-9 level, tumor response, and survival.
EUROPEAN RADIOLOGY
(2023)
Article
Multidisciplinary Sciences
Lena Wiedmann, Francesca De Angelis Rigotti, Nuria Vaquero-Siguero, Elisa Donato, Elisa Espinet, Iris Moll, Elisenda Alsina-Sanchis, Hanibal Bohnenberger, Elena Fernandez-Florido, Ronja Muelfarth, Margherita Vacca, Jennifer Gerwing, Lena-Christin Conradi, Philipp Stroebel, Andreas Trumpp, Carolin Mogler, Andreas Fischer, Juan Rodriguez-Vita
Summary: The presence of peritoneal metastasis in pancreatic cancers is associated with poor prognosis. The authors found that HAPLN1 promotes tumor cell plasticity and pro-tumoral immune microenvironment to facilitate peritoneal dissemination in pancreatic cancers.
NATURE COMMUNICATIONS
(2023)
Review
Pharmacology & Pharmacy
Maria John Newton Amaldoss, Jia-Lin Yang, Pramod Koshy, Ashwin Unnikrishnan, Charles C. Sorrell
Summary: Inorganic nanoparticles used for drug delivery in cancer treatment offer numerous advantages, such as maximizing therapeutic effect through targeting ligands and minimizing side-effects. They have shown promising combined therapeutic capabilities, including anticancer effects and inhibition of cancer cell signaling pathways. Inorganic nanoparticles serve as synergistic platforms for RNA interference and as drug delivery agents for targeting cancer cell signaling pathways.
DRUG DISCOVERY TODAY
(2022)
Article
Biochemistry & Molecular Biology
Gehan Botrus, Denise Roe, Gayle S. Jameson, Pedro Luiz Serrano Uson Junior, Ronald Lee Korn, Lana Caldwell, Taylor Bargenquast, Max Miller, Erkut Hasan Borazanci
Summary: Recent research has shown promising results in personalizing treatment for metastatic pancreatic cancer with platinum-based chemotherapy and PARP inhibitors in patients with homologous recombination deficiency (HRD). However, new strategies are needed to overcome resistance. This study documents the cases of HRD pancreatic cancer patients treated with Mitomycin C (MMC), showing positive outcomes and manageable toxicities.
Article
Oncology
Jianyun Zhao, Chengzhi Xie, Holly Edwards, Guan Wang, Jeffrey W. Taub, Yubin Ge
Article
Oncology
Zhihong J. Wang, Yubin Ge, Deniz Altinok, Janet Poulik, Sandeep Sood, Jeffrey W. Taub, Holly Edwards, Mark W. Kieran, Miller Steven
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY
(2017)
Article
Oncology
Shuang Liu, Yubin Ge, Tingting Wang, Holly Edwards, Qihang Ren, Yiqun Jiang, Chengshi Quan, Guan Wang
Article
Pharmacology & Pharmacy
Yongwei Su, Xinyu Li, Jun Ma, Jianyun Zhao, Shuang Liu, Guan Wang, Holly Edwards, Jeffrey W. Taub, Hai Lin, Yubin Ge
BIOCHEMICAL PHARMACOLOGY
(2018)
Editorial Material
Cell Biology
Holly Edwards, Yubin Ge
Article
Chemistry, Medicinal
Yi Liao, Liping Xu, Siyu Ou, Holly Edwards, Daniel Luedtke, Yubin Ge, Zhihui Qin
ACS MEDICINAL CHEMISTRY LETTERS
(2018)
Article
Cell Biology
Daniel A. Luedtke, Yongwei Su, Shuang Liu, Holly Edwards, Yue Wang, Hai Lin, Jeffrey W. Taub, Yubin Ge
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
(2018)
Review
Pharmacology & Pharmacy
Tristan Knight, Daniel Luedtke, Holly Edwards, Jeffrey W. Taub, Yubin Ge
BIOCHEMICAL PHARMACOLOGY
(2019)
Article
Oncology
Andrew Volk, Kaiwei Liang, Praveen Suraneni, Xinyu Li, Jianyun Zhao, Marinka Bulic, Stacy Marshall, Kirthi Pulakanti, Sebastien Malinge, Jeffrey Taub, Yubin Ge, Sridhar Rao, Elizabeth Bartom, Ali Shilatifard, John D. Crispino
Article
Oncology
Fangbing Liu, Hasini A. Kalpage, Deying Wang, Holly Edwards, Maik Huettemann, Jun Ma, Yongwei Su, Jenna Carter, Xinyu Li, Lisa Polin, Juiwanna Kushner, Sijana H. Dzinic, Kathryn White, Guan Wang, Jeffrey W. Taub, Yubin Ge
Article
Cell Biology
Hanxi Yu, Shuangshuang Wu, Shuang Liu, Xinyu Li, Yuqing Gai, Hai Lin, Yue Wang, Holly Edwards, Yubin Ge, Guan Wang
Summary: This study demonstrates the synergistic antileukaemic activity between XPO1 inhibitors and Bcl-2 inhibitors in AML, which is mediated through DNA damage and inhibition of DNA repair mechanisms. These findings provide a new molecular basis for the clinical evaluation of this combination therapy.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
(2022)
Review
Oncology
Tristan E. Knight, Holly Edwards, Soheil Meshinchi, Jeffrey W. Taub, Yubin Ge
Summary: This article discusses the use of new drugs targeting FLT3 gene mutations in acute myeloid leukemia (AML), the mechanisms of resistance developed by cancer cells, and how to overcome this resistance. Compared to traditional chemotherapy, these targeted agents can precisely disrupt key pathways within cancer cells, revolutionizing the treatment of AML.
Article
Cell Biology
Shuangshuang Wu, Holly Edwards, Deying Wang, Shuang Liu, Xinan Qiao, Jenna Carter, Yue Wang, Jeffrey W. Taub, Guan Wang, Yubin Ge
Summary: This study investigated the combination of the selective Mcl-1 inhibitor AZD5991 with FLT3 inhibitors gilteritinib and MRX-2843 in treating AML, finding that the combinations synergistically induce apoptosis in AML cells with FLT3 mutations, suggesting potential for further development.
Review
Biochemistry & Molecular Biology
Jenna L. Carter, Katie Hege, Jay Yang, Hasini A. Kalpage, Yongwei Su, Holly Edwards, Maik Huttemann, Jeffrey W. Taub, Yubin Ge
SIGNAL TRANSDUCTION AND TARGETED THERAPY
(2020)
Article
Hematology
Jeffrey W. Taub, Jason N. Berman, Johann K. Hitzler, April D. Sorrell, Norman J. Lacayo, Kelley Mast, David Head, Susana Raimondi, Betsy Hirsch, Yubin Ge, Robert B. Gerbing, Yi-Cheng Wang, Todd A. Alonzo, Dario Campana, Elaine Coustan-Smith, Prasad Mathew, Alan S. Gamis
Review
Oncology
Xinru Zhou, Yin Jia, Chuanbin Mao, Shanrong Liu
Summary: Small extracellular vesicles (sEVs), such as exosomes, have emerged as crucial targets for liquid biopsy and promising drug delivery vehicles in tumor progression. They can serve as biomarkers for tumor diagnosis and as drug carriers for cancer treatment.
Article
Oncology
Ruochan Chen, Ju Zhu, Xiao Zhong, Jie Li, Rui Kang, Daolin Tang
Summary: The interplay between autophagy and apoptosis plays a crucial role in tumorigenesis and cancer therapy, with HMGB1 serving as a key regulator in these processes.
Article
Oncology
Zongfu Pan, Xixuan Lu, Tong Xu, Jinming Chen, Lisha Bao, Ying Li, Yingying Gong, Yulu Che, Xiaozhou Zou, Zhuo Tan, Ping Huang, Minghua Ge
Summary: This study uncovered the emerging role of HN1 in promoting dedifferentiation of anaplastic thyroid cancer (ATC) cells. HN1 negatively regulated the thyroid differentiation markers and had an inhibitory effect on the transcriptional activation of CTCF, thereby influencing the chromatin accessibility of thyroid differentiation genes.
Article
Oncology
Yi Qin, Shengjun Xiong, Jun Ren, Gautam Sethi
Summary: Autophagy plays an important regulatory role in glioblastoma, and its dysregulation can lead to drug resistance and radioresistance. It also affects stem cell characteristics, overall growth, and metastasis. Therefore, autophagy is a promising target for glioblastoma therapy.
Article
Oncology
Katsuya Nagaoka, Xuewei Bai, Dan Liu, Kevin Cao, Joud Mulla, Chengcheng Ji, Hongze Chen, Muhammad Azhar Nisar, Amalia Bay, William Mueller, Grace Hildebrand, Jin-Song Gao, Shaolei Lu, Hiroko Setoyama, Yasuhito Tanaka, Jack R. Wands, Chiung-Kuei Huang
Summary: This study found that serum 2-OG levels in cholangiocarcinoma patients are associated with the effectiveness of chemotherapy. Patients with progressive disease showed significantly higher levels of serum 2-OG compared to stable disease and partial response patients. The study also revealed that overexpression of ASPH mimics the effects of 2-OG, and knockdown of ASPH improves chemotherapy. Targeting ASPH enhances the effects of chemotherapy by modulating ATM and ATR, two key regulators of DDRs.
